Listen on the go
    • Faculty & Disclosures
    Dr Andrew Wotherspoon

    Royal Marsden Hospital,
    London, UK

    Dr Andrew Wotherspoon is a consultant histopathologist at the Royal Marsden Hospital in London, UK, which is one of the largest cancer centres in Europe, a post he has held for 26 years. He is currently clinical lead for haematopathology. read more

    During his histopathology training, and subsequently as a diagnostic haematopathologist, Dr Wotherspoon developed an interest in the pathobiology of indolent lymphomas and chronic leukaemias. He has a particular interest in extranodal and splenic B-cell lymphoma and has made important contributions to the understanding of extranodal marginal zone lymphoma. After joining the Royal Marsden Hospital, he developed an additional special interest in the pathology of carcinoma of the digestive system.

    Dr Wotherspoon has authored over 330 research papers, 25 book chapters and three books. He has contributed to conferences and symposia in over 24 countries. He is currently past president of the European Association for Haematopathology. He has been a member of the council of the British Division of the International Academy of Pathology and is a member of the Medical Advisory Panel Lymphoma Action.

    Dr Andrew Wotherspoon has no financial interests/relationships or affiliations in relation to this activity.
    Dr Andrea Cercek

    Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Dr Andrea Cercek is a board-certified medical oncologist specializing in the treatment of patients with gastrointestinal (GI) cancers, particularly colorectal cancer (CRC), appendix cancer and cholangiocarcinoma.
    read more

    Dr Cercek is the founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer. This clinic, the first of its kind in the world, is dedicated solely to the specific needs of people under 50 years who have CRC or other GI cancers.

    Dr Cercek’s research is focused on the development of novel systemic and regional therapies, including approaches based on tumour genomics, with the goal of improving outcomes while minimizing treatment-related toxicities.

    Dr Andrea Cercek discloses: Advisory board/panel fees from Bayer, GlaxoSmithKline, Merck, Pfizer, Roche and Seagen. Grants/research support fees from GlaxoSmithKline and Seagen.
    Dr Elena Elez

    Vall d'Hebron University Hospital, Barcelona, Spain

    Dr Elena Elez is a medical oncology consultant at Vall d’Hebron University Hospital and a senior investigator at Vall d’Hebron Institute of Oncology (VHIO). read more

    Since her appointment in 2007, Dr Elez has participated as principal investigator and sub-investigator in many clinical trials with molecular therapy primarily directed to the signalling pathway of the MAP kinases in metastatic colorectal cancer (CRC). The results of this research have been crucial for the consolidation of the VHIO’s Gastrointestinal and Endocrine Tumors Group as a reference in the CRC research field, enabling the leadership of one of the most relevant collaborative clinical projects in oncology at European level.

    Dr Elez has played a key role in the development of a research programme in the mutated BRAF CRC patient population. The results of this research have been highly productive, leading to a number of publications in journals such as Nature Medicine and The New England Journal of Medicine. She is also involved in international collaborative projects focused on translational research in CRC in areas such as liquid biopsy and the microbiome, among others. Dr Elez is particularly involved in training and education and leads the young oncologists section at the Spanish Society of Medical Oncology and chairs the VHIO educational programme.

    Dr Elena Elez discloses: Advisory board/panel fees from Amgen, Bayer, Hoffmann-La Roche, Merck Serono, MSD, Novartis, Organon, Pierre Fabre, Sanofi, Seagen and Servier. Other financial or material support from Amgen, Array BioPharma, AstraZeneca, BeiGene, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Debiopharm, Genentech, HalioDX, Hoffmann-La Roche, Hutchison MediPharma, Janssen, MedImmune, Menarini, Merck, MSD, Merus, Mirati Therapeutics, Novartis, Pfizer, PharmaMar, Sanofi, Servier and Taiho Pharma.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Colorectal Cancer

    An Introduction to Colorectal Cancer

    Colorectal cancer (CRC) is the third leading cause of cancer death worldwide. The mainstay of treatment for advanced disease is chemotherapy combined with angiogenesis inhibitors and epidermal growth factor receptor (EGFR) inhibitors, but outcomes and toxicity are highly variable. Recent advances include combined small molecule/monoclonal antibody therapies for CRC with the V600E mutation in the BRAF gene for metastatic disease and immune checkpoint inhibition.

    Browse our selection of video highlights and short articles from the conference hub, which provide insights into the latest updates from major conferences, and a collection of peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.

    Colorectal Cancer Content

    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 34 mins
    touchEXPERT OPINIONS
    Fulfilling the potential of HER2-targeting in colorectal cancer: An update on detection and management
    CE/CME ACCREDITED Dr Andrew Wotherspoon, Dr Andrea Cercek, Dr Elena Elez

    Watch three experts provide insights on detecting HER2 amplifications, guideline-recommended HER2-targeted therapies in mCRC and future perspectives.

    Learning objectives
    Learning Objectives
    • Discuss the importance of and approaches for detecting HER2 amplifications in patients with CRC
    • Summarize clinical efficacy data for guideline-recommended HER2-targeted treatments for patients with mCRC
    • Appraise investigational evidence and future perspectives for emerging HER2-targeting approaches in HER2-amplified CRC
    Colorectal Cancer
    Developed by Touch
    Thierry André, ASCO 2023: The SOLISTICE phase III study, trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer
    Watch Time: 6 mins

    The SOLISTICE phase III study aimed to assess trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer. In this touchONCOLOGY interview, we speak with Dr Thierry André (Hôpital Saint-Antoine, Paris, France) to discuss the rationale for the use of trifluridine/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer, the secondary endpoint of overall survival and the key […]

    Colorectal Cancer, Gastrointestinal Cancers
    Developed by Touch
    Ben Weinberg, ASCO 2023: Highlights from the PROSPECT, AtezoTRIBE, D-ToRCH and DESTINY-CRC02 trials
    Watch Time: 9 mins

    touchONCOLOGY spoke with editorial board member Ben Weinberg (Georgetown University, Washington, DC, USA) to discuss his highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. This includes data from the Plenary Session randomized phase 3 noninferiority PROSPECT trial, showing that neoadjuvant FOLFOX with selective use of 5-FU chemoradiotherapy (5-FU CRT) […]

    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 45 mins
    touchPANEL DISCUSSION
    Optimizing strategies for the treatment of colorectal cancer in the biomarker era
    CE/CME ACCREDITED Dr Kei Muro, Dr Chiara Cremolini, Dr Rachel Riechelmann Translations available:

    Dr Muro, Dr Cremolini and Dr Riechelmann discuss how biomarkers can guide treatment choices for patients with colorectal cancer.

    Learning objectives
    Learning Objectives
    • Compare and contrast the available techniques for biomarker testing recommended for patients with CRC
    • Compare and contrast the available techniques for biomarker testing recommended for patients with CRC
    • Review the evidence for recent and emerging targeted therapy options for CRC
    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 47 mins
    touchMDT
    How can HER2-targeted therapies be incorporated into the management of patients with CRC?
    CE/CME ACCREDITED Prof. Andrea Sartore-Bianchi, Dr Evgeny Yakirevich, Dr Kristen Ciombor, Dr Kelley Rone, Mr Scott Wilson

    Hear multidisciplinary team and patient perspectives on the management of HER2-positive colorectal cancer.

    Learning objectives
    Learning Objectives
    • Summarize how to test for HER2 amplifications in patients with CRC and how to interpret the results
    • Discuss how HER2-targeted agents can be incorporated into the management of patients with CRC
    • Outline how the multidisciplinary team can support patients with HER2+ CRC
    Colorectal Cancer, Gastrointestinal Cancers
    Watch Time: 34 mins
    touchPANEL DISCUSSION
    What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?
    CE/CME ACCREDITED Dr Ian Chau, Dr Antonia Sepulveda, Dr Silvia Marsoni

    Watch three experts discuss testing and treatment guidelines for HER2+ colorectal cancer (CRC) and clinical trial data for HER2-targeted therapies.

    Learning objectives
    Learning Objectives
    • Explain the testing methods used to identify patients with human epidermal growth factor receptor 2-positive (HER2+) colorectal cancer (CRC) and the interpretation of the results
    • Summarize the current guidelines for managing patients with HER2+ CRC
    • Discuss the recent efficacy and safety data for HER2-targeted agents in CRC
    Lung Cancer, Colorectal Cancer
    Watch Time: 30 mins
    touchTALKS
    Investigating KRASG12C inhibitors: How might they improve outcomes for patients with solid tumours?
    Prof. Tony Mok Translations available:

    Prof. Tony Mok discusses the role of KRAS mutations in solid tumours and the impact of KRASG12C inhibitors on patient outcomes.

    Learning objectives
    Learning Objectives
    • Describe the role of KRAS in tumourigenesis and the implications of the KRASG12C mutation for patients with solid tumours
    • Evaluate the efficacy and safety of KRASG12C inhibitors in advanced and metastatic KRAS-mutated solid tumours
    • Formulate strategies to overcome intrinsic or acquired resistance to KRASG12C-directed therapies
    Colorectal Cancer
    Treatment Options in BRAF-mutant Metastatic Colorectal Cancer
    Marco Cefali, Maria Celeste Palmarocchi, Sara De Dosso

    touchREVIEWS in Oncology & Haematology. 2022;18(2):103-6 DOI: https://doi.org/10.17925/OHR.2022.18.2.103

    Until recently, treatment options for metastatic colorectal cancer (CRC) have been limited to a cytotoxic chemotherapy with or without an anti-epithelial growth-factor receptor (EGFR) monoclonal antibody, namely cetuximab and panitumumab, or an anti-angiogenic agent such as bevacizumab, aflibercept or ramucirumab. For subsequent lines of treatment, the tyrosine kinase inhibitor regorafenib is an important part of […]

    Colorectal Cancer
    Developed by Touch
    Benjamin Weinberg, ASCO 2022: Highlights of ASCO in colorectal cancer, dostarlimab and the DYNAMIC study
    Watch Time: 8 mins

    Professor Benjamin Weinberg (Georgetown University, Washington, DC, USA) discusses the highlights of colorectal cancer at ASCO 2022. A subset of colorectal cancer is mismatch repair deficient and is responsive to PD-1 blockade in the metastatic setting. This led to the phase II study where dostarlimab, an anti PD-1 monoclonal antibody, was administered to patients with […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72